CAR-T CDMOs — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform

CAR-T manufacturers on CDMO Signal: 31 listed. 6 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Bristol Myers Squibb (CGT Mfg) (in-house manufacturer, Signal Score 87), Novartis (in-house manufacturer, Signal Score 85.4) and City of Hope (T Cell Manufacturing) (academic or national centre, Signal Score 84). Outside that set, higher Signal Scores on this list include Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-10-20. Methodology.

CAR-T CDMOs with the most regulatory evidence on file

Novartis
85.4
Basel, Switzerland
17 FDA inspections · 51 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-24 · NAI
See the evidence →
AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Charles River Laboratories
86.3
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
9 FDA inspections · 11 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-01 · NAI
See the evidence →
Bristol Myers Squibb (CGT Mfg)
87.0
Bothell, WA · Warren, NJ
8 FDA inspections · 2 EMA/MHRA GMP certs
Last FDA inspection: 2026-04-28 · NAI
See the evidence →
Minaris Advanced Therapies
83.1
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
3 FDA inspections · 4 EMA/MHRA GMP certs
Last FDA inspection: 2025-11-25 · NAI
See the evidence →
31
CDMOs tracked
31
Fully scored
9
With FDA records
48
FDA inspections
113
EMA/MHRA GMP certs

CAR-T CDMOs manufacture engineered T-cell products, combining viral-vector transduction, T-cell activation and expansion, and rapid release testing — usually as autologous, per-patient batches on tight vein-to-vein timelines.

Choosing a CAR-T CDMO depends on autologous vs allogeneic experience, in-house vs sourced vector, closed-system processing, and chain-of-identity logistics, alongside a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 24 NAI (no action), 24 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (35), Austria (30), Denmark (23), Slovenia (13), Germany (12).

Last updated 2026-10-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
2
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
3
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
4
SC
Prague, Czech Republic
81.6 100.0 0 insp · 5 GMP None on file — —
5
NV
Morris Plains, NJ · Stein, CH
Fully evidenced
Also makes its own products
81.4 97.4 2 insp · 0 GMP 2025-07-11 · VAI Constrained 284 programs
6
CF
Les Ulis, FR
80.3 100.0 0 insp · 4 GMP None on file — —
7
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
8
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
9
MB
Bergisch Gladbach, Germany
Fully evidenced
73.0 100.0 0 insp · 2 GMP None on file — 8 programs
10
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
11
PBI
Pennington, NJ · Nanjing, CN
64.0 — — None on file — —
12
HG
Yokohama, Japan
Also makes its own products
63.0 — — None on file — —
13
OB
Hamilton, ON
61.5 — 0 insp · 2 GMP None on file — —
14
MS
Princeton, NJ
59.0 — — None on file — —
15
EB
Waltham, MA
Hiring · 8 open roles
59.0 — — None on file — —
16
EX
La Rochelle, France
Hiring · 3 open roles
59.0 — — None on file — —
17
CZ
Cologne, Germany
59.0 — — None on file — —
18
AS
Lake Nona, FL
Hiring · 8 open roles
59.0 — — None on file — —
19
CTP
Melbourne, Australia
59.0 — — None on file — —
20
PO
San Diego, CA
Hiring · 3 open roles
Also makes its own products
58.7 — — None on file — 6 programs
21
TR
Kusatsu, Shiga Prefecture, Japan
57.9 — — None on file — 8 programs
How we score CDMOs →

What to evaluate in a CAR-T CDMO

Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

In-house vs sourced vector — how CAR-T CDMOs differ

CAR-T needs a lentiviral or retroviral vector to transduce patient T cells. CDMOs that produce vector in-house eliminate one supply-chain seam and shorten tech-transfer paths, but often at higher cost and narrower serotype flexibility. CDMOs that source vector externally can pair with specialized viral vector CDMOs — see the Lentiviral Vector CDMO ranking — but must coordinate two contracts and comparability datasets. Sponsors should also ask whether the CDMO's cell therapy site is on the same campus as vector production; geographic co-location reduces shipping, transfer, and validation overhead.

Which CAR-T CDMOs handle allogeneic programs?

Most CAR-T CDMO capacity today is designed around autologous per-patient batching. Allogeneic CAR-T — using donor cells expanded to master cell banks — requires different process design and typically larger batch scale. CDMO profile pages flag "cell therapy" and "car-t" modality tags; CDMOs marked with both, and with capacity signals indicating larger-batch infrastructure, are the candidates for allogeneic programs. Sponsors should specifically ask about closed-system automation designed for the target manufacturing scale (per-donor batches vs unit-per-patient).

Commercial CAR-T CDMO capabilities

Commercial CAR-T manufacturing — supporting an approved product — is currently done by a small set of CDMOs (or in-house at the innovator). The commercial-scale CAR-T filter surfaces CDMOs with top-quartile Signal Score. Commercial CAR-T requires not just cGMP capacity but validated chain-of-identity, real-time release testing infrastructure, and demonstrated vein-to-vein turnaround performance under commercial volumes. Sponsors moving from clinical to commercial should assume 12–18 months of tech transfer even with a CDMO that has commercial CAR-T experience.

How CDMO Signal computes the CAR-T ranking

The CAR-T Signal Score is the platform's standard four-pillar composite. Quality Compliance (35%) leans on FDA inspection classifications (NAI, VAI, OAI), Warning Letter history, and EMA/MHRA GMP certificate density. Operations (25%) reflects ClinicalTrials.gov sponsor and program footprint matched to each CDMO — for CAR-T this pillar carries strong signal since clinical activity closely tracks real manufacturing depth. Financial Stability (20%) draws on public/private status and parent-company backing. Capacity Intelligence (20%) counts the manufacturing sites and modalities listed on the profile; job postings are not a score input. Press announcements and SEC filings are shown on profiles as company signals and do not change any score. Full weightings at cdmosignal.com/methodology.

CAR-T CDMOs — Frequently Asked Questions

Who are the top CAR-T CDMOs?
Among CAR-T manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Bristol Myers Squibb (CGT Mfg), Novartis, City of Hope (T Cell Manufacturing). The table above is the full list. CDMOs cannot pay to change a score.
How many CAR-T CDMOs have FDA inspection records?
CDMO Signal tracks 9 CAR-T CDMOs with FDA inspection records and 113 EMA/MHRA GMP certificates across the group.
What should I look for in a CAR-T CDMO?
Confirm vector supply (in-house or coordinated), autologous logistics and vein-to-vein turnaround, closed-system scalable processing for parallel patients, and a clean FDA and EMA/MHRA record.
Do CAR-T CDMOs make their own viral vectors?
Some produce lentiviral or retroviral vector in-house; others coordinate an external vector CDMO. In-house vector can shorten timelines and de-risk supply. Check each profile's modality coverage above.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this CAR-T shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Cell Therapy CDMOs Lentiviral Vector CDMOs Gene Editing CDMOs
Other Modalities
AAV Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy Viral Vector